Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
life sciences
national
5
×
national blog main
san francisco blog main
san francisco top stories
boston blog main
boston top stories
boulder/denver blog main
boulder/denver top stories
clinical trials
detroit blog main
detroit top stories
indiana blog main
indiana top stories
national top stories
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
amgen
eli lilly
fda
fremanezumab
teva pharmaceutical
bristol-myers squibb
calcitonin gene-related peptide
drug prices
eptinezumab
erenumab
galcanezumab
migraine
What
approval
5
×
drug
5
×
new
amgen
bio
class
companies
developed
fda
migraine
nod
roundup
won
advanced
alnylam’s
amgen’s
arguments
bff
big
biogen’s
biopharmaceutical
candidates
carries
commercialized
competitors
conference
convo
deals
decades
devoted
disease
drugs
earlier
easl
europe
european
failures
form
gene
gets
Language
unset
Current search:
drug
×
national
×
approval
×
@xconomy.com
4 years ago
Amgen’s Osteoporosis Drug Wins European Nod, With a Heart Warning
@xconomy.com
5 years ago
At Big Neuro Meeting, Migraine Drug Competitors to Make Oral Arguments
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
5 years ago
Bio Roundup: EASL Does It, Alnylam’s BFF, Gene Therapy Deals & More
@xconomy.com
6 years ago
Amgen Migraine Drug Gets FDA Nod, First in New Class of Medicines